Talk:Virosome
Latest comment: 2 years ago by PrimeBOT in topic Wiki Education Foundation-supported course assignment
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
|
![]() | This article may be too technical for most readers to understand.(September 2010) |
Wiki Education Foundation-supported course assignment
editThis article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Rachaelmendoza.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 12:28, 17 January 2022 (UTC)
Assessment comment
editThe comment(s) below were originally left at Talk:Virosome/Comments, and are posted here for posterity. Following several discussions in past years, these subpages are now deprecated. The comments may be irrelevant or outdated; if so, please feel free to remove this section.
Virosomes therefore represent an innovative, broadly applicable adjuvant and carrier system with prospective applications in areas beyond conventional vaccines. They are one of only three adjuvant systems widely approved by regulatory authorities and the only one that has carrier capabilities. This reads like an advertisement -- not really surprising given that it is directly quoted from the site of a company that sells IP relating to virosomes =651On. A greater diversity of sources is needed here. --DavidHopwood 00:18, 28 July 2007 (UTC) |
Last edited at 00:18, 28 July 2007 (UTC). Substituted at 10:02, 30 April 2016 (UTC)